Needle Free Drug Delivery Devices Market Analysis By Technology (Jet Injectors, Inhaler Technology, Transdermal Patch, Novel Needle Free Technologies), By Application (Vaccine Delivery, Pain Management, Insulin Delivery For Diabetes, Pediatric Injections), And Segment Forecasts To 2024
The global needle free drug delivery devices market is expected to reach USD 14.6 billion by 2024, according to a new report published by Grand View Research, Inc. The increasing prevalence of chronic diseases such as Hepatitis B, Hepatitis C, and AIDS due to the extensive use of injections is a potent driver of the needle-free drug delivery devices market.
Additionally, the rising need for self-administration of drugs as in the case of diabetes and pain-free drug delivery have consequentially boosted the industry share of needle-free drug delivery devices.
Moreover, controlled dosing ability, minimal damage to skin and rapid drug administration are the key associated benefits driving the physician preference thereby fueling the demand for the market. Furthermore, the increasing focus on the development of portable delivery devices has a high, positive impact on the needle-free drug delivery devices market.
These aforementioned advantages related to needle-free drug delivery devices are expected to serve as key driving factors spurring the growth of the needle-free drug delivery devices market over the forecast period.
Further key findings from the study suggest:
Jet injectors dominated the technology segment with a market share of over 30.0%, with respect to revenue in 2015, owing to its high usage rate and wide applicability in delivering a large range of drugs
On the basis of application, the insulin delivery devices segment held the largest share of over 33.0% in 2015 owing to the high demand for painless insulin delivery by patients coupled with the requirement of insulin at regular intervals in diabetic patients, thus facilitating the growth of this segment. As per the WHO, the global diabetes prevalence is rising at a rate of 8.5%, thereby propelling the demand for needle-free insulin delivery devices.
In 2015, North America dominated the needle-free drug delivery devices market at over 43.0%. The presence of multinational conglomerates, favorable reimbursement policies, and sophisticated healthcare infrastructure are key growth drivers of this regional market
Asia Pacific is expected to be growing at the fastest CAGR of over 12.0% during the forecast period owing to the rising disposable income and the increasing number of investments by the western manufactures in the emerging economies pertinent to manufacturing facilities and untapped opportunities
Some key players operational in this industry include PharmaJet, Valeritas, Antares Pharma, Inc., Bioject Medical Technologies, Inc., 3M, Glide Pharmaceutical Technologies Ltd., Zogenix, Inc., Akra Dermojet, Injex Pharma AG, PenJet Corporation, and D'Antonio Consultants International, Inc.
These industry players are adopting strategies such as technology-oriented advancements, new product development, and strategic collaborations, such as mergers & acquisitions to maximize their industry share. In April 2014, Bioject medical Technologies, Inc. appointed Needle Free Solutions LLC as the exclusive distributor of its product Biojector 2000 with a view to enhance its distribution channel across North America.
Additionally, the rising need for self-administration of drugs as in the case of diabetes and pain-free drug delivery have consequentially boosted the industry share of needle-free drug delivery devices.
Moreover, controlled dosing ability, minimal damage to skin and rapid drug administration are the key associated benefits driving the physician preference thereby fueling the demand for the market. Furthermore, the increasing focus on the development of portable delivery devices has a high, positive impact on the needle-free drug delivery devices market.
These aforementioned advantages related to needle-free drug delivery devices are expected to serve as key driving factors spurring the growth of the needle-free drug delivery devices market over the forecast period.
Further key findings from the study suggest:
Jet injectors dominated the technology segment with a market share of over 30.0%, with respect to revenue in 2015, owing to its high usage rate and wide applicability in delivering a large range of drugs
On the basis of application, the insulin delivery devices segment held the largest share of over 33.0% in 2015 owing to the high demand for painless insulin delivery by patients coupled with the requirement of insulin at regular intervals in diabetic patients, thus facilitating the growth of this segment. As per the WHO, the global diabetes prevalence is rising at a rate of 8.5%, thereby propelling the demand for needle-free insulin delivery devices.
In 2015, North America dominated the needle-free drug delivery devices market at over 43.0%. The presence of multinational conglomerates, favorable reimbursement policies, and sophisticated healthcare infrastructure are key growth drivers of this regional market
Asia Pacific is expected to be growing at the fastest CAGR of over 12.0% during the forecast period owing to the rising disposable income and the increasing number of investments by the western manufactures in the emerging economies pertinent to manufacturing facilities and untapped opportunities
Some key players operational in this industry include PharmaJet, Valeritas, Antares Pharma, Inc., Bioject Medical Technologies, Inc., 3M, Glide Pharmaceutical Technologies Ltd., Zogenix, Inc., Akra Dermojet, Injex Pharma AG, PenJet Corporation, and D'Antonio Consultants International, Inc.
These industry players are adopting strategies such as technology-oriented advancements, new product development, and strategic collaborations, such as mergers & acquisitions to maximize their industry share. In April 2014, Bioject medical Technologies, Inc. appointed Needle Free Solutions LLC as the exclusive distributor of its product Biojector 2000 with a view to enhance its distribution channel across North America.
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Research Methodology
1.2. Research Scope & Assumptions
1.3. List of Data Sources
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Needle Free drug delivery devices market- Industry Snapshot and Key Buying Criteria, 2015
CHAPTER 3. NEEDLE FREE DRUG DELIVERY DEVICES INDUSTRY OUTLOOK
3.1. Needle Free drug delivery devices market Segmentation
3.2. Needle Free drug delivery devices market Size and Growth Prospects
3.3. Needle Free drug delivery devices market Dynamics
3.3.1. Market Driver Analysis
3.3.1.1. Rising incidences of respiratory diseases
3.3.1.2. Technological advancements
3.3.2. Market Restraint Analysis
3.3.2.1. Complex regulatory framework
3.4. Key Opportunities Prioritized
3.5. Needle Free drug delivery devices Competitive Landscape, 2015
3.5.1. Company Market Share Analysis, 2015
3.5.2. Competitive Landscape: Market Position Analysis (based on products, regional presence, and strategic initiatives)
3.6. Industry Analysis - Porter's
3.7. Needle Free drug delivery devices market PESTEL Analysis, 2015
CHAPTER 4. NEEDLE FREE DRUG DELIVERY DEVICES TECHNOLOGY OUTLOOK
4.1. Needle Free drug delivery devices market Share By technology, 2015 & 2024
4.2. Needle Free drug delivery devices
4.2.1. Needle Free drug delivery devices Market Estimates and Forecasts, 2014 - 2024
4.2.2. Jet Injectors
4.2.2.1. Jet Injectors Market Estimates and Forecasts, 2014 - 2024
4.2.3. Inhaler Technology
4.2.3.1. Inhaler Technologies Market Estimates and Forecasts, 2014 - 2024
4.2.4. Transdermal Patch Technology
4.2.4.1. Transdermal Patch Technology Market Estimates and Forecasts, 2014 - 2024
4.2.5. Novel Needle Free Technologies
4.2.5.1. Novel Needle Free Technologies Market Estimates and Forecasts, 2014 - 2024
CHAPTER 5. NEEDLE FREE DRUG DELIVERY DEVICES APPLICATION OUTLOOK
5.1. Needle Free drug delivery devices market Share By Application, 2015 & 2024
5.2. Vaccine Delivery
5.2.1. Vaccine Delivery Market Estimates and Forecasts, 2014 - 2024
5.3. Pain Management
5.3.1. pain Management Market Estimates and Forecasts, 2014 - 2024
5.4. Obstructive Sleep Apnea
5.4.1. Obstructive Sleep Apnea Market Estimates and Forecasts, 2014 - 2024
5.5. Insulin Delivery for Diabetes
5.5.1. Insulin Delivery for Diabetes Market Estimates and Forecasts, 2014 - 2024
5.6. Pediatric Injections
5.6.1. Pediatric Injections Market Estimates and Forecasts, 2014 - 2024
5.7. Others
5.7.1. Others Market Estimates and Forecasts, 2014 - 2024
CHAPTER 6. NEEDLE FREE DRUG DELIVERY DEVICES REGIONAL OUTLOOK
6.1. Needle Free drug delivery devices market Share By Region, 2015 & 2024
6.2. North America
6.2.1. North America Market Estimates and Forecasts, By technology, 2014 - 2024 (USD Million)
6.2.1.1. U.S. Market Estimates and Forecasts
6.2.1.2. Canada Market Estimates and Forecasts
6.2.2. North America Market Estimates and Forecasts, By Application, 2014 - 2024 (USD Million)
6.2.2.1. U.S. Market Estimates and Forecasts
6.2.2.2. Canada Market Estimates and Forecasts
6.3. Europe
6.3.1. Europe Market Estimates and Forecasts, By technology, 2014 - 2024 (USD Million)
6.3.1.1. UK Market Estimates and Forecasts
6.3.1.2. Germany Market Estimates and Forecasts
6.3.2. Europe Market Estimates and Forecasts, By Application, 2014 - 2024 (USD Million)
6.3.2.1. UK Market Estimates and Forecasts
6.3.2.2. Germany Market Estimates and Forecasts
6.4. Asia Pacific
6.4.1. Asia Pacific Market Estimates and Forecasts, By technology, 2014 - 2024 (USD Million)
6.4.1.1. Japan Market Estimates and Forecasts
6.4.1.2. China Market Estimates and Forecasts
6.4.1.3. India Market Estimates and Forecasts
6.4.2. Asia Pacific Market Estimates and Forecasts, By Application, 2014 - 2024 (USD Million)
6.4.2.1. Japan Market Estimates and Forecasts
6.4.2.2. China Market Estimates and Forecasts
6.4.2.3. India Market Estimates and Forecasts
6.5. Latin America
6.5.1. Latin America Market Estimates and Forecasts, By technology, 2014 - 2024 (USD Million)
6.5.1.1. Brazil Market Estimates and Forecasts
6.5.1.2. Mexico Market Estimates and Forecasts
6.5.2. Latin America Market Estimates and Forecasts, By Application, 2014 - 2024 (USD Million)
6.5.2.1. Brazil Market Estimates and Forecasts
6.5.2.2. Mexico Market Estimates and Forecasts
6.6. MEA
6.6.1. MEA Market Estimates and Forecasts, By technology, 2014 - 2024 (USD Million)
6.6.1.1. South Africa Market Estimates and Forecasts
6.6.2. MEA Market Estimates and Forecasts, By Application, 2014 - 2024 (USD Million)
6.6.2.1. South Africa Market Estimates and Forecasts
CHAPTER 7. COMPETITIVE LANDSCAPE
7.1. Antares Pharma, Inc.
7.1.1. Company Overview
7.1.2. Financial Performance
7.1.3. Product Benchmarking
7.1.4. Strategic Initiatives
7.2. Glide Pharmaceutical Technologies Ltd
7.2.1. Company Overview
7.2.2. Financial Performance
7.2.3. Product Benchmarking
7.2.4. Strategic Initiatives
7.3. Injex Pharma AG
7.3.1. Company Overview
7.3.2. Financial Performance
7.3.3. Product Benchmarking
7.3.4. Strategic Initiatives
7.4. 3M
7.4.1. Company Overview
7.4.2. Financial Performance
7.4.3. Product Benchmarking
7.4.4. Strategic Initiatives
7.5. PharmaJet
7.5.1. Company Overview
7.5.2. Financial Performance
7.5.3. Product Benchmarking
7.5.4. Strategic Initiatives
7.6. Zogenix, Inc.
7.6.1. Company Overview
7.6.2. Financial Performance
7.6.3. Product Benchmarking
7.6.4. Strategic Initiatives’
7.7. BioJect Medical Technologies, Inc.
7.7.1. Company Overview
7.7.2. Financial Performance
7.7.3. Product Benchmarking
7.7.4. Strategic Initiatives
7.8. Penjet Corporation
7.8.1. Company Overview
7.8.2. Financial Performance
7.8.3. Product Benchmarking
7.8.4. Strategic Initiatives
7.9. Valeritas
7.9.1. Company Overview
7.9.2. Financial Performance
7.9.3. Product Benchmarking
7.9.4. Strategic Initiatives
7.10. D'Antonio Consultants International, Inc.
7.10.1. Company Overview
7.10.2. Financial Performance
7.10.3. Product Benchmarking
7.10.4. Strategic Initiatives
7.11. Akra Dermojet
7.11.1. Company Overview
7.11.2. Financial Performance
7.11.3. Product Benchmarking
7.11.4. Strategic Initiatives
1.1. Research Methodology
1.2. Research Scope & Assumptions
1.3. List of Data Sources
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Needle Free drug delivery devices market- Industry Snapshot and Key Buying Criteria, 2015
CHAPTER 3. NEEDLE FREE DRUG DELIVERY DEVICES INDUSTRY OUTLOOK
3.1. Needle Free drug delivery devices market Segmentation
3.2. Needle Free drug delivery devices market Size and Growth Prospects
3.3. Needle Free drug delivery devices market Dynamics
3.3.1. Market Driver Analysis
3.3.1.1. Rising incidences of respiratory diseases
3.3.1.2. Technological advancements
3.3.2. Market Restraint Analysis
3.3.2.1. Complex regulatory framework
3.4. Key Opportunities Prioritized
3.5. Needle Free drug delivery devices Competitive Landscape, 2015
3.5.1. Company Market Share Analysis, 2015
3.5.2. Competitive Landscape: Market Position Analysis (based on products, regional presence, and strategic initiatives)
3.6. Industry Analysis - Porter's
3.7. Needle Free drug delivery devices market PESTEL Analysis, 2015
CHAPTER 4. NEEDLE FREE DRUG DELIVERY DEVICES TECHNOLOGY OUTLOOK
4.1. Needle Free drug delivery devices market Share By technology, 2015 & 2024
4.2. Needle Free drug delivery devices
4.2.1. Needle Free drug delivery devices Market Estimates and Forecasts, 2014 - 2024
4.2.2. Jet Injectors
4.2.2.1. Jet Injectors Market Estimates and Forecasts, 2014 - 2024
4.2.3. Inhaler Technology
4.2.3.1. Inhaler Technologies Market Estimates and Forecasts, 2014 - 2024
4.2.4. Transdermal Patch Technology
4.2.4.1. Transdermal Patch Technology Market Estimates and Forecasts, 2014 - 2024
4.2.5. Novel Needle Free Technologies
4.2.5.1. Novel Needle Free Technologies Market Estimates and Forecasts, 2014 - 2024
CHAPTER 5. NEEDLE FREE DRUG DELIVERY DEVICES APPLICATION OUTLOOK
5.1. Needle Free drug delivery devices market Share By Application, 2015 & 2024
5.2. Vaccine Delivery
5.2.1. Vaccine Delivery Market Estimates and Forecasts, 2014 - 2024
5.3. Pain Management
5.3.1. pain Management Market Estimates and Forecasts, 2014 - 2024
5.4. Obstructive Sleep Apnea
5.4.1. Obstructive Sleep Apnea Market Estimates and Forecasts, 2014 - 2024
5.5. Insulin Delivery for Diabetes
5.5.1. Insulin Delivery for Diabetes Market Estimates and Forecasts, 2014 - 2024
5.6. Pediatric Injections
5.6.1. Pediatric Injections Market Estimates and Forecasts, 2014 - 2024
5.7. Others
5.7.1. Others Market Estimates and Forecasts, 2014 - 2024
CHAPTER 6. NEEDLE FREE DRUG DELIVERY DEVICES REGIONAL OUTLOOK
6.1. Needle Free drug delivery devices market Share By Region, 2015 & 2024
6.2. North America
6.2.1. North America Market Estimates and Forecasts, By technology, 2014 - 2024 (USD Million)
6.2.1.1. U.S. Market Estimates and Forecasts
6.2.1.2. Canada Market Estimates and Forecasts
6.2.2. North America Market Estimates and Forecasts, By Application, 2014 - 2024 (USD Million)
6.2.2.1. U.S. Market Estimates and Forecasts
6.2.2.2. Canada Market Estimates and Forecasts
6.3. Europe
6.3.1. Europe Market Estimates and Forecasts, By technology, 2014 - 2024 (USD Million)
6.3.1.1. UK Market Estimates and Forecasts
6.3.1.2. Germany Market Estimates and Forecasts
6.3.2. Europe Market Estimates and Forecasts, By Application, 2014 - 2024 (USD Million)
6.3.2.1. UK Market Estimates and Forecasts
6.3.2.2. Germany Market Estimates and Forecasts
6.4. Asia Pacific
6.4.1. Asia Pacific Market Estimates and Forecasts, By technology, 2014 - 2024 (USD Million)
6.4.1.1. Japan Market Estimates and Forecasts
6.4.1.2. China Market Estimates and Forecasts
6.4.1.3. India Market Estimates and Forecasts
6.4.2. Asia Pacific Market Estimates and Forecasts, By Application, 2014 - 2024 (USD Million)
6.4.2.1. Japan Market Estimates and Forecasts
6.4.2.2. China Market Estimates and Forecasts
6.4.2.3. India Market Estimates and Forecasts
6.5. Latin America
6.5.1. Latin America Market Estimates and Forecasts, By technology, 2014 - 2024 (USD Million)
6.5.1.1. Brazil Market Estimates and Forecasts
6.5.1.2. Mexico Market Estimates and Forecasts
6.5.2. Latin America Market Estimates and Forecasts, By Application, 2014 - 2024 (USD Million)
6.5.2.1. Brazil Market Estimates and Forecasts
6.5.2.2. Mexico Market Estimates and Forecasts
6.6. MEA
6.6.1. MEA Market Estimates and Forecasts, By technology, 2014 - 2024 (USD Million)
6.6.1.1. South Africa Market Estimates and Forecasts
6.6.2. MEA Market Estimates and Forecasts, By Application, 2014 - 2024 (USD Million)
6.6.2.1. South Africa Market Estimates and Forecasts
CHAPTER 7. COMPETITIVE LANDSCAPE
7.1. Antares Pharma, Inc.
7.1.1. Company Overview
7.1.2. Financial Performance
7.1.3. Product Benchmarking
7.1.4. Strategic Initiatives
7.2. Glide Pharmaceutical Technologies Ltd
7.2.1. Company Overview
7.2.2. Financial Performance
7.2.3. Product Benchmarking
7.2.4. Strategic Initiatives
7.3. Injex Pharma AG
7.3.1. Company Overview
7.3.2. Financial Performance
7.3.3. Product Benchmarking
7.3.4. Strategic Initiatives
7.4. 3M
7.4.1. Company Overview
7.4.2. Financial Performance
7.4.3. Product Benchmarking
7.4.4. Strategic Initiatives
7.5. PharmaJet
7.5.1. Company Overview
7.5.2. Financial Performance
7.5.3. Product Benchmarking
7.5.4. Strategic Initiatives
7.6. Zogenix, Inc.
7.6.1. Company Overview
7.6.2. Financial Performance
7.6.3. Product Benchmarking
7.6.4. Strategic Initiatives’
7.7. BioJect Medical Technologies, Inc.
7.7.1. Company Overview
7.7.2. Financial Performance
7.7.3. Product Benchmarking
7.7.4. Strategic Initiatives
7.8. Penjet Corporation
7.8.1. Company Overview
7.8.2. Financial Performance
7.8.3. Product Benchmarking
7.8.4. Strategic Initiatives
7.9. Valeritas
7.9.1. Company Overview
7.9.2. Financial Performance
7.9.3. Product Benchmarking
7.9.4. Strategic Initiatives
7.10. D'Antonio Consultants International, Inc.
7.10.1. Company Overview
7.10.2. Financial Performance
7.10.3. Product Benchmarking
7.10.4. Strategic Initiatives
7.11. Akra Dermojet
7.11.1. Company Overview
7.11.2. Financial Performance
7.11.3. Product Benchmarking
7.11.4. Strategic Initiatives
